• Corpus ID: 8825073

Antiarthritic properties and unique pharmacologic profile of a potential chrysotherapeutic agent: S K & F D-30162.

  title={Antiarthritic properties and unique pharmacologic profile of a potential chrysotherapeutic agent: S K \& F D-30162.},
  author={Donald T. Walz and M. J. Dimartino and Lawrence William Chakrin and Blaine M. Sutton and Anne M. Misher},
  journal={The Journal of pharmacology and experimental therapeutics},
  volume={197 1},
SK&F D-39162, a potential chrysotherapeutic agent, on oral administration was effective in suppressing the development of inflammatory lesions and 7S anti-sheep red blood cell antibody formation in adjuvant arthritic rats. Oral absorption of SK&F D-39162 was indicated by the presence of serum gold levels. In contrast to orally administered SK&F D-39162, gold sodium thiomalate administered intramuscularly at equivalent gold doses, appeared to be less effective in suppressing the primary and… 

Effect of auranofin, a new antiarthritic agent, on immune complex-induced release of lysosomal enzymes from human leukocytes

The results suggest that the therapeutic action of auranofin may be caused, at least in part, by inhibition of LER and/or decreases in immune-complex formation.

Auranofin: a unique oral chrysotherapeutic agent.

Antiarthritic synergism of combined oral and parenteral chrysotherapy

The present studies open the possibility that combined treatment with oral and injectable gold provide a new approach for chrysotherapy with an increased antiarthritic potency.

Inhibition of lysosomal enzyme release from rat leukocytes by auranofin

The results of this investigation suggest that the antiarthritic activity of auranofin may be caused at least in part, by inhibition of lysosomal enzyme release and/or cellular processing of antigens.

Action of gold salts in some inflammatory and immunological models

Some gold salts do possess anti-inflammatory activity with a potency similar to that of indomethacin, as indicated by observations in kaolin-induced rat paw oedema and in Wistar rats and Lewis rats.

Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Auranofin is a useful addition to the limited list of agents with disease-modifying potential presently available for the treatment of rheumatoid arthritis and will doubtless generate much interest as its final place in therapy becomes better defined through additional well-designed studies and wider clinical experience.

Auranofin. New oral gold compound for treatment of rheumatoid arthritis.

A follow-up study under placebo of clinical and laboratory changes in the same patients during another 3-month period showed that IgG serum levels rapidly reverted preceding a flare up of disease activity after withdrawal of the drug, confirming a direct role in cause-effect relation played by the new oral gold compound.

Immunopharmacology of gold sodium thiomalate and auranofin (SK&F D-39162)

Results were suggested to be due to the possible stimulation by gold of T effector as well as T suppressor lymphocytes, thus explaining the condition dependency of the immunoregulation.

Recent developments in disease-modifying antirheumatic drugs.

  • I. Hunneyball
  • Biology, Medicine
    Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques
  • 1980
This chapter will concentrate on the recent developments in the disease-modifying antirheumatic agents.